AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies
-- Key Data are New Releases for the Company Building on Milestones with Recent FDA Meetings and Technology Discoveries --
DENVER, April 20 /PRNewswire-FirstCall/ -- DXL625 monoclonal antibodies appear to be superior to commercial-stage antibodies in their ability
to attach and deplete NHL ...
ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canada's Ability to Deal with Biological Threats
HALIFAX, April 14 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has announced the signing of a 3-year research agreement with Defence Research and Development Canada (DRDC). The research collaboration involves the preclinical application of IVT's DepoVax(TM) ...
Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
- Data Further Supports High Degree of Tumor Targeting Specificity for Bavituximab, Currently in Phase II Cancer Trials in Combination with Chemotherapy -
- Imaging Study Also Suggests Potential Utility of Anti-PS Agents for Molecular Imaging ...
Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function
Findings Presented at American Academy of Pediatrics National Conference & Exhibition
SAN FRANCISCO and EAST NORRITON, Pa., Oct. 29 /PRNewswire/ -- Tengion,
Inc., a leader in regenerative medicine, announced today that findings from
a preclinical study being presen...
First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
SAN FRANCISCO, Oct. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics,
Inc. (CTI) (Nasdaq and MTAX: CTIC) announced preclinical data presented at
the 19th annual AACR-NCI-EORTC Symposium show its bis-platinate drug
candidates, CT-47613 and CT-47609, kill tumors refractory to currently
Researchers improve ability to write and store information on electronic devices
New research led by the U.S. Department of Energy's Argonne National Laboratory physicist Matthias Bode provides a more thorough understanding of new mechanisms, which makes it possible to switch a magnetic nanoparticle without any magnetic field and may enable computers to more accurately write a...
ThalesNano Flow Reactor Realizes Microwave Speed With Scale-up Ability
BUDAPEST, Hungary, LONDON and PRINCETON, N.J., Feb. 10 /PRNewswire/ -- ThalesNano today announced a big step forward in the evolution of flow chemistry with the independent publication of results that prove that flow chemistry can match microwave chemistry in terms of speed, but with the ability
Dry adhesive based on carbon nanotubes gets stronger, with directional gripping ability
The race for the best "gecko foot" dry adhesive got a new competitor this week with a stronger and more practical material reported in the journal Science by a team of researchers from four U.S. institutions.
Scientists have long been interested in the ability
of gecko lizards to scurry up wall...
...hotonics, medicine, and imaging and sensing. The key to success will be the ability
to synthesis nanocrystals with desired physical properties. This will requi...elds of science."
Says Dahmen, "From a microscopist's point of view, the ability
to observe nanoparticles in liquid solution opens new opportunities in an a...
KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid
...de (but are not limited to) the following: (1) the ability
to continue as a going concern; (2) changes in the...ctual or potential competitors or to the Company's ability
to market generic products due to brand company pa...(26) sale or licensing of certain assets; (27) the ability
to monetize the auction rate securities (ARS) curr...
Schering-Plough Shareholders Approve Merger With Merck
...keting actions); scientific developments relating to marketed products or pipeline projects; media and societal reaction to such developments; and the ability
of Schering-Plough and Merck to obtain governmental approvals of the merger on the proposed terms and schedule. For further details of these and othe...
Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading
...According to several authorities in the field, this is incorrect, as both studies actually demonstrate a significant improvement in patients' pain and ability
to function normally.
Tory McJunkin, MD, co-founder of Arizona Pain Specialists, has a personal connection because his grandmother recently had...
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
...ommon stock on the NYSE Amex may further limit our ability
to access the capital markets. Any issuance of add...d in the forward-looking statements, including our ability
to raise additional funds or enter strategic allia...or our products, which would materially impair our ability
to generate revenue, or we may not be able to rais...
Novavax Reports Second Quarter 2009 Financial Results
...e risks and uncertainties, including the Company's ability
to progress any product candidates in preclinical ...nt venture and licensing agreements; the Company's ability
to enter into future collaborations with industry ...claims and other intellectual property rights; our ability
to obtain rights to technology; competition for cl...
Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
...casted results. A number of factors, including our ability
to successfully complete the clinical trials requi...us to file a new drug application for CPP-109, our ability
to complete such trials on a timely basis within the budgets we establish for such trials, our ability
to protect our intellectual property and those oth...
NeurogesX Reports Second Quarter 2009 Results
...on to our PDUFA date. With Astellas as our partner, we are confident in its ability
to effectively launch Qutenza in the European Union and we are now focusing...penses and cash burn rate as well as receipt of any payments from partners; ability
to secure adequate or additional financing; and the sufficiency of cash res...
Viral Genetics Creates Subsidiary to Develop Cancer Therapy
...olic disruption technology" (MDT), which focuses on blocking a tumor cell's ability
to generate energy from glucose or from fatty acids. That process has been... of the assumptions could be inaccurate, including, but not limited to, the ability
of Viral Genetics to establish the efficacy of VGV-1 in the treatment of an...
American Oriental Bioengineering Reports Second Quarter 2009 Financial Results
...e revenue growth and consistently generate cash
despite the uncertain regulatory environment in China's healthcare sector, and
we are confident in our ability
to be a top-five pharmaceutical company in
The Company will hold a conference call at 8:00 am ET on August 7, 2...
SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
...act 96 system - accuracy, sensitivity, and now the ability
to cost-effectively run fewer samples, make this n... of the results of those trials, and the Company's ability
to expand its genetic analysis platforms, as well ...ks and uncertainties associated with the Company's ability
to develop and commercialize new technologies and ...
deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2009 Financial Results
...ient financing to continue as a going concern, our ability
develop and market diagnostic products, the lev...mpounds and the completion of clinical trials, our ability
collaborative relationships, the effect of...ulatory approval processes, market acceptance, our ability
to obtain and
protect intellectual property rights...
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
...regarding the potential
benefits of CUDC- 305; its ability
to further progress its programs under
- Curis faces risks relating to its ability
to enter into and
maintain planned collabora...ates under its
targeted cancer programs, its ability
to maintain its current
collaborations with ...
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
... in preventing pulmonary emboli, and to assess the ability
to retrieve the device from the body up to 175 day...ges that could impact our existing products or our ability
to develop and commercialize future products; comp...actual results. These operating risks include: our ability
to attract and retain qualified personnel; our...
Repligen Reports First Quarter Fiscal Year 2010 Financial Results
..., synthetic human secretin, designed to assess the ability
of RG1068 in combination with magnetic resonance i...nships, the market acceptance of our products, our ability
to compete with larger, better financed pharmaceut...r uncertainty of product revenues and profits, our ability
to generate future revenues, our...
Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
...ies. Specifically, the risks and uncertainties include statements about our ability
to continue to reduce our operating expenses, our ability
to continue to raise capital as needed to fund our operations, the developm...
Exciton Technologies receives FDA approval to market exSALT(TM)
...e issuance of additional patents and the Company's ability
to protect its intellectual property, involve know...s to pursue research and development projects, the ability
to economically manufacture its products, the pote...tion of clinical studies and trials, the Company's ability
to successfully commercialize its products, the...
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
...ding projections of the Company's cash position and expected use of cash during 2009, actual results may differ based on market factors, the company's ability
to execute its operational and budget plans, and its achievement of milestones and receipt of milestone payments from Shire. Additionally, all forward...
ADVENTRX Pharmaceuticals Announces Financing
... reduced workforce and leadership by officers who do not have substantial previous experience in executive leadership roles will negatively impact its ability
to raise capital or maintain effective disclosure controls and procedures or internal control over financial reporting; the risk that ADVENTRX's commo...
Knighted Adds Industry Pioneer and Entrepreneur to Senior Management Team
...ng efficiencies and productivity. Knighted is well positioned to enhance their customers' global supply chains for today and the future."
to attract talented individuals like Mr. Wilensky confirms that Knighted is bringing new products to market that will change the way supply chain mana...
Advanced Life Sciences to Host 2009 Second Quarter Financial Results Conference Call and Webcast
...ance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability
to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Excha...
NxStage Reports Second Quarter 2009 Financial Results
...and 4 percent, respectively, when compared with revenue for the second quarter of 2008.
"Our second quarter results demonstrate our continued ability
to improve key financial metrics including revenue, gross margin, adjusted EBITDA and cash usage," stated Jeffrey H. Burbank, Chief Executive Officer ...
The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.
...clinical research with this generous donation and hope that other pharmaceutical companies will follow its lead."
"We are proud to support the ability
of the NIH to pursue new and cutting-edge research by freeing up much needed resources," said Marc Cluzel, M.D. Senior Vice President Research & D...
Microbia Names John McCarthy to Senior Management Team
"I'm very pleased to be joining Microbia at this important time in its development," stated Mr. McCarthy. "The ability
to build a unique, low-cost and highly valuable specialty biochemicals franchise based on renewable raw materials presents a tremendous market opportu...
Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
...ated operating losses, need for future capital and ability
to obtain future funding; competition from third parties; the Company's ability
to preserve and protect intellectual property righ...k of sales and marketing experience; the Company's ability
to attract and retain key personnel; changes in te...
Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress
...uncertainties include, but are not limited to: our ability
to increase usage of our tests; the risk that we m...iated with the regulation of our tests by FDA; our ability
to compete against third parties; our ability
to develop and commercialize new tests; unanticipa...
Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
obtaining regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company's ability
obtain additional funding required to conduct its research, development and
commercialization activities. Please refer to the company's filings wit...
SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS
...73, S2383 and other sweetness enhancers; Senomyx's ability
or Firmenich's ability
to commercialize S2383 when anticipated and market...luding without limitation statements regarding our ability
to successfully complete development activities fo...
Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
...s in patients with acute heart failure and mild to moderate renal insufficiency. Additional exploratory endpoints will include assessments of CD-NP's ability
to relieve symptoms of acute heart failure and its effects on biomarkers of heart failure and renal function. The study is expected to enroll approxi...
Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
... clinic for the benefit of clinicians and HCV patients."
"The unique two component nature of the NS4B-RNA target appears to decrease the virus' ability
to escape inhibition by the small molecule inhibitors in development at Eiger, and that should decrease HCV resistance to this type of antiviral thera...
Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
...ge of Quill SRS for laparoscopic procedures is the ability
to close a wound using Quill without the surgeon h...S is that the even distribution of tension and its ability
to maintain the tension along the length of the su...ges that could impact our existing products or our ability
to develop and commercialize future products; comp...
ETC Biomedical Announces Chamber Sale in India
...pany or its business, (vii) statements made about the possible outcomes of litigation involving the Company, (viii) statements regarding the Company's ability
to obtain financing to support its operations and other expenses, and (ix) statements preceded by, followed by or that include the words, "may," "coul...